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Background: Ageing is a common factor in the onset neuronal dysfunction and 
neurodegenerative diseases. Serum level of melatonin (N-acetyl-5-methoxytryptamine), a free 
radical scavenger, reduces significantly during normal ageing and in neurodegeneration.  
Methods: To test the therapeutic potential of melatonin on function during normal ageing, we 
carried out an assessment of neuronal function in six months, nine months, twelve months and 
twenty-four months old male Sprague Dawley (SD) rats with 0.1mg/kg exogenous melatonin. 
Data was analyzed using one way analysis of variance (ANOVA) and Student-Knewman 
Keuls post-hoc test. Results: In six months old SD rats, melatonin treatment for two months 
restored motor function in the Chimney test. Furthermore, melatonin administration improved 
exploratory behavior and motor activity in ageing rats in the Elevated plus Maze (EPM) task. 
Finally, only 33% of melatonin treated rats had died at the termination of the experiment while 
all controls had 100% mortality. Conclusion: Melatonin may be a beneficial therapeutic agent 






Normal ageing often leads to the decline in cell function and 
the onset of major degenerative diseases. In particular the 
brain and skeletal muscle are affected leading to reduced 
function and susceptibility to age-related disease. There has 
been a search for therapeutic targets to boost function during 
normal ageing. Among such proposed compounds is 
melatonin- (N-acetyl-5-methoxytryptamine). Serum 
melatonin levels decrease with increasing age (Waldhauser et 
al., 1988). Experiments in mice observed an extension of life 
span with administration of melatonin but suggested 
replicative studies to justify the findings (Pierpaoli and 
Regelson, 1994).  Melatonin administration also increased 
life span in fruit fly (Bovilla et al., 2002). However, the 
available evidence of the role of melatonin has not validated 
its therapeutic use convincingly (Karasek, 2007). Uniquely 
among many compounds, melatonin has no known LD50 and 
it is nearly non-toxic (Gitto et. al., 2012). Given that ageing 












affects the entire human population with a corresponding rise 
in the number of age-related disease, it is important to look 
into possible therapeutic agent that will preserve function 
during ageing. Currently, available data and conflicting 
reports have not allowed for the approval of melatonin as a 
remedy for age-related cell dysfunction. Hence, this study 
further investigates the therapeutic potential of melatonin in 




Twenty-seven (27) male Sprague Dawley Rats were 
used for this study. The animals were raised in the 
animal house of the Lagos State University College of 
Medicine, Lagos, Nigeria. Institutional guidelines for 
the care, use and handling of animals were followed. 
Animals had 12-hour light and 12-hour darkness and 
were fed with rat chow and water ad libitum.  
 
The Elevated plus Maze (EPM) Task  
Locomotor activity and exploratory behavior was 
studied using the Elevated plus Maze Task (Lister, 
1987; Brown et al., 1999). The Elevated plus Maze 
(EPM) box was built according the description of 
Lister, 1987 with some modifications in the dimension 
to allow for the size of adult and aged rats. The 
Elevated plus Maze Box was made from clear plexi-
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glass and ply-wood which forms a plus. The Plus Maze 
was elevated from the ground by 60cm. The open arms 
(50cm X 10cm) of the maze were made of ply wood 
with an elevation of about 2cm. In the closed arms 
(50cm X 10cm), clear plexi-glass 50cm X 40cm was 
fixed at two adjacent sides. This allowed the observer 
to view the behavior of the animal when it is on this 
end of the box. A ply wood of 40cm X 10cm closed up 
the closed arm of the elevated plus maze. Behavioural 
assessment was carried out in diffused lighting using 
the Any Maze behavioural tracking system connected 
to an overhead camera. Animals were introduced into 
the EPM box for five minutes and behavioural 
parameters were measured or scored. The EPM box 
was cleaned with 70% ethanol before introducing the 
next animal to remove any olfactory cues.  
 
 
   
Fig. 1: 
 The Elevated Plus Maze Box 
 
Chimney Test  
Motor function was assessed using the Chimney Test. The 
Chimney test was first described by Boissier and colleagues 
in 1960. The inability of an animal to climb backward up 
through a plastic or glass tube within a given period of time 
is regarded as an indication of neurologic impairment 
(Boissier et. al., 1960) and this was used to assess motor 
function in rodent animals. The chimney comprises a glass 
tube, diameter of 44mm and length 320mm in length. Rats 
were introduced into the glass tube after placing the tube in a 
horizontal position and allowing the rats to walk into the 
tube. When the animal reaches the end of the tube, the tube is 
inverted or turned vertically so that the animal is in an 
upside-down position. This triggers an escape response and 
the animal starts to climb backwards up the tube. Using a 
stop watch, the time it took for the rats to climb out was 
measured (3min cut off time and 6 trials for each animal).  
 
Drug administration  
Melatonin (0.1mg/kg) was administered subcutaneously to 
animals late evening for eight weeks. Melatonin (Sigma 
Aldrich) was freshly  prepared for daily administration. 
Melatonin (Sigma Aldrich) was dissolved in 10% ethanolic 
saline before administration.  
 
Statistical Analysis 
Data was plotted as mean + standard error of mean. 
Statistical analysis was carried out using one way ANOVA 
followed by Student-Knewman Keuls post-hoc test on the 
ANYMAZE Software behavioral tracking system. Student t-
test (unpaired) was used where appropriate.  
 
RESULTS 
Total Measures of Activity in the Elevated plus Maze 
(EPM) task 
The overall measure of activity in the two zones, A and B 
(i.e. arms) in the Elevated plus Maze (EPM) task is shown in 
fig. 2a, 2b, 2c, and 2d. Melatonin administration increased 
total distance covered and average speed in the EPM box in 
all age groups (Fig. 2a and 2b), although these changes were 
not significant. Similarly, the total number of grooming 
episodes was reduced in 24 months old rats by melatonin 
treatment (Fig. 2c). In contrast, we found a significant 
increase in the duration of head dip behaviour in melatonin 
treated 24 months old rats compared with untreated controls 
of the same age (Fig. 2d).  
 
Zone A (Closed arm) activity measures in the EPM task 
The time spent in the closed arm of the EPM box was shorter 
in melatonin treated 24 months old rats (Fig. 3a). The mean 
average speed in the closed arm was increased with 
melatonin treatment, although these parameters were not 
statistically significant (Fig. 3a and 3b). The time inactive in 
the closed arm and the number of grooming episodes varied 
directly with the total time spent in the closed arm in all the 
age groups (Fig. 3c and 3d).      
 
Zone B (Open arm) activity measures in the EPM task 
In 9 months and 12 months old rats, melatonin treatment did 
not have any significant effect on the distance covered in the 
open arm of the EPM box, however, in the 24 months old 
rats, melatonin administration significantly raised distance 
covered and the number of head dips in the open arms (Fig. 
4a and 4b). Similarly, the number of grooming episodes and 
the frequency of grooming was significantly raised in the 24 
months old melatonin treated rats compared with untreated 
controls of the same age (Fig. 4c and 4d). 
 
Chimney Test 
In the Chimney test, melatonin significantly improved motor 
function in 6 months old rats which received melatonin 
treatment for eight (8) weeks compared with controls (Fig. 
5).  
Longevity Studies 
At the termination of the experiment, 100% death was 
recorded in the ethanolic saline treated 24 months old rats 
group, while only 33% death was recorded in the melatonin 
treated 24 months old rats group (Fig. 6). 
 
DISCUSSION 
Our findings show that there were improvements in 
motor function and activity in the melatonin treated 24 
months old rats which were not significant (Fig. 2a, 2b, 
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2c). Early melatonin intervention before rats reach old 
age is therefore recommended for future studies. In 
addition, closed arm (Zone A) activity observed in the 
EPM task showed that melatonin has a potential to alter 
function favourably as ageing sets in (Fig. 3a, 3b, 3c,   
 
Fig. 2: (a) Total distance travelled in the EPM in ethanolic saline (ES) and melatonin (M) treated rats. ANOVA F (5, 11) = 
1.9044; p>0.05. (b) Average speed in the EPM in ethanolic saline (ES) and melatonin (M) treated rats with age. ANOVA F (5, 
11) = 1.8891; p>0.05. (c) Time spent grooming in the EPM in ethanolic saline (ES) and melatonin (M) treated rats.  
ANOVA  F (5, 11) = 0.0501; p>0.05. (d) Total time of head dips in the EPM in ethanolic saline (ES) and melatonin (M) 
treated rats. ANOVA  F (5, 11) = 1.1480; p>0.05. *p<0.05; 24 months (ES) vs 24 months M 
 
 
Fig. 3: (a) Time spent in the Zone A, the closed arm of the EPM in ethanolic saline (ES) and melatonin (M) treated rats. 
ANOVA F (5, 11) = 1.9639; p>0.05.(b) Average speed in the closed arm of the EPM in ethanolic saline and melatonin treated 
rats. F (5, 11) = 1.0137; p>0.05 (c) Time inactive in the closed arm of the EPM in ethanolic saline (ES) and melatonin (M) 
treated rats. F (5, 11) = 2.1273; p>0.05 (d) Grooming in the closed arm of the EPM in ethanolic saline (ES) and melatonin (M) treated rats. 
F (5, 11) = 0.7104; p>0.05 
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Fig. 4:  (a) Distance travelled in the open arm of the EPM in ethanolic saline (ES) and melatonin (M) treated rats. ANOVA F 
(5, 11) = 1.6593; p>0.05. *p<0.05; 24 months (ES) vs 24 months (M). (b) Number of Head dips in the open arm of the EPM in 
ethanolic saline (ES) and melatonin (M) treated rats. ANOVA F (5, 11) =   0.9717; p>0.05 *p<0.05; 24 months (ES) vs 24 
months (M). (c) Number of grooming episodes in  the open arm of the EPM in ethanolic saline (ES) and elatonin (M) treated 
rats. ANOVA F (5, 11) =3.2353; *p<0.05 *p<0.05; 24 months (ES) vs 24 months (M) (d) Frequency of grooming in the open 
arm of the EPM in ethanolic (ES) and melatonin (M) treated rats. ANOVA F (5, 11) = 3.4123;* p<0.05. *p<0.05; 24 months 
(ES) vs 24 months (M) 
 
3d). We hypothesize that at old age during normal 
ageing, the total restoration of normal function using 
melatonin treatment may depend on the integrity of 
melatonin receptors. Convincingly, melatonin receptors 
have been found to mediate some of the therapeutic 
actions of melatonin (Dragicevic et al., 2011, Wang et 
al., 2011) and in the absence of the receptors, melatonin 
may not be able to restore or improve function during 
old age (Dragicevic, 2011). 
Furthermore, open arm activity was improved in 
melatonin treated 24 months old animals compared 
with untreated controls, Fig. 4a, 4b, 4c, 4d.  Head-dip 
behavior, a characteristic feature of explorative 
behavior in the open arms of the EPM box (Brown et 
al., 2009) was significantly raised in melatonin treated 
24 months old rats (Fig.4b). Although grooming 
behavior in rodents is considered a displacement 
behavior (Espejo et al., 1997), excessive grooming may 
be a sign of genetic neurological disorder according to 
Greer and Capecchi, 2002. The results show a  
 
reduction in excessive grooming in the closed arm of 
the EPM box in melatonin treated 24 months old rats  
(Fig. 3d). Interestingly, melatonin treated 24 months 
old rats’ show grooming behavior in the open arm of 
the EPM box (Fig. 4c and 4d). This grooming behavior 
seen in the open arm of the EPM box in this group is 
within the normal grooming limit of about 10 – 15% of 
the mean total time spent by rodents when placed in a 
novel environment as reported by Jolles et al., 1979. In 
this study, melatonin sustained normal grooming (Fig. 
2b) but prevented excessive grooming which is 
characteristic of neuronal dysfunction or nervous 
disorder. 
In the chimney test, melatonin restored motor function 
in 6 months old treated male Sprague Dawley rats 
which received melatonin for eight weeks (Fig. 5). This 
improvement seen with melatonin treatment is an 
indication of an age-related downturn in normal 
function in the animals and this is consistent with an 
earlier report that the decline in motor function occurs 
Therapeutic potential of melatonin in ageing rats 
40                          J. Afr. Ass. Physiol. Sci. 3 (1): July, 2015                                                Idowu and Olatunji-Bello 
 
before old age (Li et al., 2013). Herein, we report that 
melatonin carries out its positive influences on neuronal 
function effectively during the early stages of ageing. 
This may account for the inability of melatonin to 
significantly improve or preserve some motor functions 




Fig. 5: Chimney test in ethanolic Saline (ES) treated and 




Fig. 6: Percentage death in 24 months old male Sprague 
Dawley rats after ethanolic saline (ES) and melatonin (M) 
treatment for eight weeks. 
 
 
Finally, our longevity studies with exogenous 
melatonin administration show an increase in life span 
in the melatonin treated old rats. At the time of 
concluding the experiments after melatonin 
administration, we recorded 100% death in the 24 
months old ethanolic saline treated rats while only 33% 
death was recorded in the 24 months old melatonin 
treated rats (Fig. 6). Although there are conflicting 
reports on the ability of melatonin to extend life span 
(Pierpaoli and Regelson, 1994; Karasek, 2007), this 
study has contributed to the available data on the role 
of melatonin in life span extension. Hence, we 
conclude that, melatonin is able to improve neuronal 
function when administered early and that melatonin 
may be a potent therapeutic agent during normal 
ageing.  
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